Tang Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Tang Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.4M	Hold	4,814,700	–	–	1.02%	23
2026 Q1	$25.9M	Hold	4,814,700	–	–	1.32%	20
2025 Q4	$17.2M	Sell	4,814,700 -11,500	-0.2%	-$36.5K	0.85%	27
2025 Q3	$14M	Sell	4,826,200 -63,000	-1%	-$215K	0.54%	47
2025 Q2	$17.6M	Buy	4,889,200 +89,200	+2%	+$266K	0.89%	36
2025 Q1	$14.4M	Buy	4,800,000 +11,088	+0.2%	+$34.6K	0.79%	35
2024 Q4	$16M	Buy	4,788,912 +181,852	+4%	+$604K	1.06%	25
2024 Q3	$15.4M	Buy	4,607,060 +130,319	+3%	+$473K	1.1%	28
2024 Q2	$14.8M	Buy	4,476,741 +400,000	+10%	+$1.49M	1.51%	22
2024 Q1	$16.5M	Hold	4,076,741	–	–	1.71%	17
2023 Q4	$12.4M	Buy	4,076,741 +476,741	+13%	+$1.44M	1.15%	24
2023 Q3	$10.8M	Buy	3,600,000 +573,545	+19%	+$1.95M	1.52%	20
2023 Q2	$11.3M	Buy	3,026,455 +2,023,873	+202%	+$7.58M	1.67%	20
2023 Q1	$3.36M	Buy	+1,002,582	New	+$4.07M	0.5%	50

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Tang Capital Management's AVIR Position: Q2 2026 in Review

Tang Capital Management held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 4,814,700 shares worth $22.4M. The position accounts for 1.02% of the portfolio, ranked #23.

Tang Capital Management first reported a position in AVIR in Q1 2023 and has held it in 14 quarters since. The position peaked at $25.9M in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Tang Capital Management held 4,814,700 shares of Atea Pharmaceuticals worth $22.4M as of Q2 2026.
Tang Capital Management left its Atea Pharmaceuticals share count unchanged in Q2 2026.
Atea Pharmaceuticals made up 1.02% of Tang Capital Management's portfolio in Q2 2026, its #23 holding.
Tang Capital Management first reported a position in Atea Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Tang Capital Management's Atea Pharmaceuticals position peaked at $25.9M in Q1 2026.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.